ImmunoBiology Ltd

First-In-Human Study of Immbios Novel Pneumococcal Vaccine Pnubiovax Shows Vaccine to Be Safe and Immunogenic

Antibody responses to ubiquitous antigens across strains shown, indicative of broad protection  Statistically significant increases in antibody response were achieved in the 200 (mid) and 500 µg (high) dose groups, in comparison to the placebo group  100% of subjects in the high dose group achieved a significant immune response  Study demonstrated a dose response relationship ...
ImmBio Ltd., Babraham Research Campus, Babraham, Cambridge, CB22 3AT, UK

+44 (0)1223 496117